Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis.

Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnett-Bowie SM, Finkelstein JS

The Journal of clinical endocrinology and metabolism12 May 2009Cited by 93 (Europe PMC)

PMID19435827PMCIDPMC2730878DOI10.1210/jc.2008-2630PepBankPUB-19435827

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In women and men with osteoporosis, spine BMD increased similarly during teriparatide treatment.
In plain wordsIn women and men with osteoporosis, spine bone density increased similarly during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSpine BMD during treatment
Study
n = 31
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
37 microg daily · subcutaneous · 24 monthsAs given in this study (human).
Source sentences
Summary
BMD of the spine, femoral neck, total hip, and trabecular spine increased similarly during the treatment period in men and women, whereas BMD at the radius was stable in men but decreased by 8.1 +/- 3.3% in women (P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective cohort substudy.PatientsThe study included 14 postmenopausal women and 17 eugonadal men, ages 46-85 yr, with lumbar spine or femoral neck BMD T-scores below -2.InterventionTeriparatide (37 microg sc daily) was administered for 24 months, followed by 12 months off therapy.
Report a problemFND-1943582701
02HumanObservational studyEfficacy outcome
In women and men with osteoporosis, femoral neck BMD increased similarly during teriparatide treatment.
In plain wordsIn women and men with osteoporosis, femoral neck bone density increased similarly during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD during treatment
Study
n = 31
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
37 microg daily · subcutaneous · 24 monthsAs given in this study (human).
Source sentences
Summary
BMD of the spine, femoral neck, total hip, and trabecular spine increased similarly during the treatment period in men and women, whereas BMD at the radius was stable in men but decreased by 8.1 +/- 3.3% in women (P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective cohort substudy.PatientsThe study included 14 postmenopausal women and 17 eugonadal men, ages 46-85 yr, with lumbar spine or femoral neck BMD T-scores below -2.InterventionTeriparatide (37 microg sc daily) was administered for 24 months, followed by 12 months off therapy.
Report a problemFND-1943582702
03HumanObservational studyEfficacy outcome
In women and men with osteoporosis, total hip BMD increased similarly during teriparatide treatment.
In plain wordsIn women and men with osteoporosis, total hip bone density increased similarly during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD during treatment
Study
n = 31
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
37 microg daily · subcutaneous · 24 monthsAs given in this study (human).
Source sentences
Summary
BMD of the spine, femoral neck, total hip, and trabecular spine increased similarly during the treatment period in men and women, whereas BMD at the radius was stable in men but decreased by 8.1 +/- 3.3% in women (P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective cohort substudy.PatientsThe study included 14 postmenopausal women and 17 eugonadal men, ages 46-85 yr, with lumbar spine or femoral neck BMD T-scores below -2.InterventionTeriparatide (37 microg sc daily) was administered for 24 months, followed by 12 months off therapy.
Report a problemFND-1943582703
04HumanObservational studyEfficacy outcome
In women and men with osteoporosis, trabecular spine BMD increased similarly during teriparatide treatment.
In plain wordsIn women and men with osteoporosis, trabecular spine bone density increased similarly during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular spine BMD during treatment
Study
n = 31
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
37 microg daily · subcutaneous · 24 monthsAs given in this study (human).
Source sentences
Summary
BMD of the spine, femoral neck, total hip, and trabecular spine increased similarly during the treatment period in men and women, whereas BMD at the radius was stable in men but decreased by 8.1 +/- 3.3% in women (P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective cohort substudy.PatientsThe study included 14 postmenopausal women and 17 eugonadal men, ages 46-85 yr, with lumbar spine or femoral neck BMD T-scores below -2.InterventionTeriparatide (37 microg sc daily) was administered for 24 months, followed by 12 months off therapy.
Report a problemFND-1943582704
05HumanObservational studyEfficacy outcome
In eugonadal men with osteoporosis, radius BMD remained stable during teriparatide treatment.
In plain wordsIn men with osteoporosis, forearm bone density remained stable during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeRadius BMD during treatment in men
Study
n = 17
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
37 microg daily · subcutaneous · 24 monthsAs given in this study (human).
Source sentences
Summary
BMD of the spine, femoral neck, total hip, and trabecular spine increased similarly during the treatment period in men and women, whereas BMD at the radius was stable in men but decreased by 8.1 +/- 3.3% in women (P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective cohort substudy.PatientsThe study included 14 postmenopausal women and 17 eugonadal men, ages 46-85 yr, with lumbar spine or femoral neck BMD T-scores below -2.InterventionTeriparatide (37 microg sc daily) was administered for 24 months, followed by 12 months off therapy.
Report a problemFND-1943582705
06HumanObservational studyEfficacy outcome
In postmenopausal women with osteoporosis, radius BMD decreased during teriparatide treatment.
In plain wordsIn postmenopausal women with osteoporosis, forearm bone density decreased during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseRadius BMD during treatment in women
Study
n = 14
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
37 microg daily · subcutaneous · 24 monthsAs given in this study (human).
Measurements
Radius BMD decrease
8.1%
women during treatment
Source sentences
Summary
BMD of the spine, femoral neck, total hip, and trabecular spine increased similarly during the treatment period in men and women, whereas BMD at the radius was stable in men but decreased by 8.1 +/- 3.3% in women (P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective cohort substudy.PatientsThe study included 14 postmenopausal women and 17 eugonadal men, ages 46-85 yr, with lumbar spine or femoral neck BMD T-scores below -2.InterventionTeriparatide (37 microg sc daily) was administered for 24 months, followed by 12 months off therapy.
Report a problemFND-1943582706

Studies that did not test the peptide alone8

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

07HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In eugonadal men, posterior-anterior spine BMD decreased after teriparatide cessation.
In plain wordsIn men, spine bone density decreased after teriparatide stopped.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePosterior-anterior spine BMD after discontinuation in men
Study
n = 17
Outcome group
Bone and joint · Musculoskeletal
Measurements
Spine BMD decrease
4.1%
men after cessation
Source sentences
Summary
After teriparatide was stopped, BMD at the posterior-anterior spine decreased by 7.1 +/- 3.8% in women and by 4.1 +/- 3.5% in men (P = 0.036).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective cohort substudy.PatientsThe study included 14 postmenopausal women and 17 eugonadal men, ages 46-85 yr, with lumbar spine or femoral neck BMD T-scores below -2.InterventionTeriparatide (37 microg sc daily) was administered for 24 months, followed by 12 months off therapy.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1943582708
08HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In men with osteoporosis, total hip BMD remained stable after teriparatide cessation.
In plain wordsIn men with osteoporosis, total hip bone density remained stable after teriparatide stopped.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal hip BMD after discontinuation in men
Study
n = 17
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
BMD at the total hip and femoral neck decreased by 3.8 +/- 3.9 and 3.1 +/- 4.3%, respectively, in women but remained stable in men (P < 0.05 for both sites).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective cohort substudy.PatientsThe study included 14 postmenopausal women and 17 eugonadal men, ages 46-85 yr, with lumbar spine or femoral neck BMD T-scores below -2.InterventionTeriparatide (37 microg sc daily) was administered for 24 months, followed by 12 months off therapy.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1943582711
09HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In men with osteoporosis, femoral neck BMD remained stable after teriparatide cessation.
In plain wordsIn men with osteoporosis, femoral neck bone density remained stable after teriparatide stopped.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD after discontinuation in men
Study
n = 17
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
BMD at the total hip and femoral neck decreased by 3.8 +/- 3.9 and 3.1 +/- 4.3%, respectively, in women but remained stable in men (P < 0.05 for both sites).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective cohort substudy.PatientsThe study included 14 postmenopausal women and 17 eugonadal men, ages 46-85 yr, with lumbar spine or femoral neck BMD T-scores below -2.InterventionTeriparatide (37 microg sc daily) was administered for 24 months, followed by 12 months off therapy.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1943582712
10HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In men with osteoporosis, distal radius BMD remained stable after teriparatide cessation.
In plain wordsIn men with osteoporosis, forearm bone density remained stable after teriparatide stopped.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeDistal radius BMD after discontinuation in men
Study
n = 17
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
BMD at the distal radius remained stable in men but increased in women by 1.6 +/- 3.1% (P = 0.069).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective cohort substudy.PatientsThe study included 14 postmenopausal women and 17 eugonadal men, ages 46-85 yr, with lumbar spine or femoral neck BMD T-scores below -2.InterventionTeriparatide (37 microg sc daily) was administered for 24 months, followed by 12 months off therapy.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1943582713
11HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In postmenopausal women, posterior-anterior spine BMD decreased after teriparatide cessation.
In plain wordsIn postmenopausal women, spine bone density decreased after teriparatide stopped.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePosterior-anterior spine BMD after discontinuation in women
Study
n = 14
Outcome group
Bone and joint · Musculoskeletal
Measurements
Spine BMD decrease
7.1%
women after cessation
Source sentences
Summary
After teriparatide was stopped, BMD at the posterior-anterior spine decreased by 7.1 +/- 3.8% in women and by 4.1 +/- 3.5% in men (P = 0.036).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective cohort substudy.PatientsThe study included 14 postmenopausal women and 17 eugonadal men, ages 46-85 yr, with lumbar spine or femoral neck BMD T-scores below -2.InterventionTeriparatide (37 microg sc daily) was administered for 24 months, followed by 12 months off therapy.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1943582707
12HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In postmenopausal women, total hip BMD decreased after teriparatide cessation, whereas it remained stable in men.
In plain wordsAfter teriparatide stopped, total hip bone density decreased in women but remained stable in men.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTotal hip BMD after discontinuation in women
Study
n = 14
Outcome group
Bone and joint · Musculoskeletal
Measurements
Total hip BMD decrease
3.8%
women after cessation
Source sentences
Summary
BMD at the total hip and femoral neck decreased by 3.8 +/- 3.9 and 3.1 +/- 4.3%, respectively, in women but remained stable in men (P < 0.05 for both sites).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective cohort substudy.PatientsThe study included 14 postmenopausal women and 17 eugonadal men, ages 46-85 yr, with lumbar spine or femoral neck BMD T-scores below -2.InterventionTeriparatide (37 microg sc daily) was administered for 24 months, followed by 12 months off therapy.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1943582709
13HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In postmenopausal women, femoral neck BMD decreased after teriparatide cessation, whereas it remained stable in men.
In plain wordsAfter teriparatide stopped, femoral neck bone density decreased in women but remained stable in men.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseFemoral neck BMD after discontinuation in women
Study
n = 14
Outcome group
Bone and joint · Musculoskeletal
Measurements
Femoral neck BMD decrease
3.1%
women after cessation
Source sentences
Summary
BMD at the total hip and femoral neck decreased by 3.8 +/- 3.9 and 3.1 +/- 4.3%, respectively, in women but remained stable in men (P < 0.05 for both sites).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective cohort substudy.PatientsThe study included 14 postmenopausal women and 17 eugonadal men, ages 46-85 yr, with lumbar spine or femoral neck BMD T-scores below -2.InterventionTeriparatide (37 microg sc daily) was administered for 24 months, followed by 12 months off therapy.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1943582710
14HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In postmenopausal women, distal radius BMD increased numerically after teriparatide cessation, without statistical significance.
In plain wordsIn postmenopausal women, forearm bone density increased after teriparatide stopped, but the change was not statistically significant.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeDistal radius BMD after discontinuation in women
Study
n = 14
Outcome group
Bone and joint · Musculoskeletal
Measurements
Distal radius BMD increase
1.6%
women after cessation
Source sentences
Summary
BMD at the distal radius remained stable in men but increased in women by 1.6 +/- 3.1% (P = 0.069).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective cohort substudy.PatientsThe study included 14 postmenopausal women and 17 eugonadal men, ages 46-85 yr, with lumbar spine or femoral neck BMD T-scores below -2.InterventionTeriparatide (37 microg sc daily) was administered for 24 months, followed by 12 months off therapy.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1943582714

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.